Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the purchase, the director owned 131,773 shares in the company, valued at $2,806,764.90. The trade was a 8.21% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Elanco Animal Health Trading Up 3.6%
Shares of ELAN stock opened at $22.49 on Wednesday. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.70. The company has a market capitalization of $11.17 billion, a PE ratio of 374.81, a price-to-earnings-growth ratio of 2.95 and a beta of 1.86. The firm has a 50 day moving average price of $21.79 and a two-hundred day moving average price of $18.22. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and upped their price target for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They set an "overweight" rating and a $30.00 target price on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of Elanco Animal Health in a research note on Monday. KeyCorp reissued an "overweight" rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Finally, Argus upgraded Elanco Animal Health from a "hold" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $22.78.
Check Out Our Latest Analysis on Elanco Animal Health
Institutional Trading of Elanco Animal Health
A number of hedge funds have recently made changes to their positions in the company. New Mexico Educational Retirement Board acquired a new position in shares of Elanco Animal Health in the third quarter valued at approximately $1,998,000. CTC Alternative Strategies Ltd. bought a new position in shares of Elanco Animal Health during the third quarter valued at $220,000. Allworth Financial LP lifted its holdings in shares of Elanco Animal Health by 20.0% during the third quarter. Allworth Financial LP now owns 8,445 shares of the company's stock worth $170,000 after purchasing an additional 1,410 shares during the period. Swiss Life Asset Management Ltd grew its stake in shares of Elanco Animal Health by 79.1% in the third quarter. Swiss Life Asset Management Ltd now owns 22,789 shares of the company's stock worth $459,000 after purchasing an additional 10,067 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in Elanco Animal Health in the third quarter valued at $9,762,000. 97.48% of the stock is owned by institutional investors and hedge funds.
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
